206 related articles for article (PubMed ID: 16432175)
1. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
[TBL] [Abstract][Full Text] [Related]
4. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
5. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
6. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
7. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.
Leonard K; Marugan JJ; Raboisson P; Calvo R; Gushue JM; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jul; 16(13):3463-8. PubMed ID: 16647257
[TBL] [Abstract][Full Text] [Related]
8. HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma.
Shi Y; Takenobu H; Kurata K; Yamaguchi Y; Yanagisawa R; Ohira M; Koike K; Nakagawara A; Jiang LL; Kamijo T
Eur J Cancer; 2010 Aug; 46(12):2324-34. PubMed ID: 20591651
[TBL] [Abstract][Full Text] [Related]
9. HDM2 regulation by AURKA promotes cell survival in gastric cancer.
Sehdev V; Katsha A; Arras J; Peng D; Soutto M; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Clin Cancer Res; 2014 Jan; 20(1):76-86. PubMed ID: 24240108
[TBL] [Abstract][Full Text] [Related]
10. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
11. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
12. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
Demma M; Maxwell E; Ramos R; Liang L; Li C; Hesk D; Rossman R; Mallams A; Doll R; Liu M; Seidel-Dugan C; Bishop WR; Dasmahapatra B
J Biol Chem; 2010 Apr; 285(14):10198-212. PubMed ID: 20124408
[TBL] [Abstract][Full Text] [Related]
13. Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells.
Ding L; Zhang Z; Zhao C; Chen L; Chen Z; Zhang J; Liu Y; Nie Y; He Y; Liao K; Zhang X
J Exp Clin Cancer Res; 2021 Aug; 40(1):245. PubMed ID: 34362424
[TBL] [Abstract][Full Text] [Related]
14. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
[TBL] [Abstract][Full Text] [Related]
15. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
Grasberger BL; Lu T; Schubert C; Parks DJ; Carver TE; Koblish HK; Cummings MD; LaFrance LV; Milkiewicz KL; Calvo RR; Maguire D; Lattanze J; Franks CF; Zhao S; Ramachandren K; Bylebyl GR; Zhang M; Manthey CL; Petrella EC; Pantoliano MW; Deckman IC; Spurlino JC; Maroney AC; Tomczuk BE; Molloy CJ; Bone RF
J Med Chem; 2005 Feb; 48(4):909-12. PubMed ID: 15715460
[TBL] [Abstract][Full Text] [Related]
16. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.
Zhao J; Wang M; Chen J; Luo A; Wang X; Wu M; Yin D; Liu Z
Cancer Lett; 2002 Sep; 183(1):69-77. PubMed ID: 12049816
[TBL] [Abstract][Full Text] [Related]
17. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.
Kazemi A; Safa M; Shahbazi A
Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539
[TBL] [Abstract][Full Text] [Related]
18. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
19. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma.
Isaacs JS; Saito S; Neckers LM
J Biol Chem; 2001 May; 276(21):18497-506. PubMed ID: 11279110
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]